zynerba
pharmaceuticals
provides
update
recent
milestones
meeting
food
drug
administration
fda
planned
discuss
regulatory
path
forward
children
adolescents
fragile
x
syndrome
fully
methylated
gene
newly
issued
fxs
patent
supplements
intellectual
property
protection
fda
suggests
pursuing
individual
syndromes
developmental
epileptic
encephalopathies
program
evaluation
initial
targets
late
stage
clinical
evaluation
ongoing
devon
globe
newswire
zynerba
pharmaceuticals
nasdaq
zyne
leader
innovative
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
today
provided
update
fragile
x
syndrome
fxs
developmental
epileptic
encephalopathies
dee
programs
fragile
x
syndrome
fxs
zynerba
notified
food
drug
administration
fda
meet
company
via
teleconference
fourth
quarter
discuss
pivotal
data
regulatory
path
forward
patients
fxs
fully
methylated
gene
fmet
company
also
expects
disclose
outcome
meeting
fourth
quarter
year
meeting
fda
important
milestone
patients
families
live
debilitating
behavioral
impact
fragile
x
said
armando
anido
chairman
chief
executive
officer
zynerba
ongoing
evaluation
pivotal
data
continues
clarify
impact
zygel
achieved
severely
impacted
children
adolescents
fxs
well
excellent
tolerability
profile
look
forward
discussing
pivotal
data
regulatory
path
potential
approval
fmet
patients
fda
fourth
quarter
zynerba
also
announced
patent
trademark
office
issued
us
patent
titled
treatment
fragile
x
syndrome
cannabidiol
includes
claims
directed
method
treating
fxs
comprising
administering
synthetic
purified
cannabidiol
pharmaceutically
acceptable
carrier
person
need
thereof
new
patent
expires
part
expanding
intellectual
property
portfolio
covering
zygel
developmental
epileptic
encephalopathies
dee
zynerba
concluded
iterative
meetings
fda
utilizing
written
response
wro
format
discuss
clinical
pathway
zygel
dee
fda
supports
development
program
would
treat
awareness
convulsive
seizures
however
due
heterogeneity
patients
fall
dee
umbrella
fda
suggests
zynerba
pursue
individual
syndromes
rather
considering
dee
patients
single
disorder
condition
company
process
finalizing
evaluation
epileptic
syndromes
may
pursue
zygel
appreciate
partnership
fda
thank
input
support
seek
advance
development
zygel
certain
rare
epilepsy
syndromes
continued
anido
look
forward
completing
target
assessments
communicating
path
forward
around
end
zynerba
pharmaceuticals
zynerba
pharmaceuticals
leader
transdermal
cannabinoid
therapies
rare
neuropsychiatric
disorders
committed
improving
lives
patients
families
living
severe
chronic
health
conditions
including
fragile
x
syndrome
autism
spectrum
disorder
deletion
syndrome
heterogeneous
group
rare
epilepsies
known
developmental
epileptic
encephalopathies
learn
follow
us
twitter
zynerbapharma
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
may
cases
use
terms
predicts
believes
potential
proposed
continue
estimates
anticipates
expects
plans
intends
may
could
might
words
convey
uncertainty
future
events
outcomes
identify
statements
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
company
current
expectations
management
expectations
therefore
statements
press
release
could
also
affected
risks
uncertainties
relating
number
factors
including
following
company
cash
cash
equivalents
may
sufficient
support
operating
plan
long
anticipated
company
expectations
projections
estimates
regarding
expenses
future
revenue
capital
requirements
incentive
tax
credit
eligibility
collectability
timing
availability
need
additional
financing
company
ability
obtain
additional
funding
support
clinical
development
programs
results
cost
timing
company
clinical
development
programs
including
delays
clinical
trials
relating
enrollment
site
initiation
clinical
results
company
product
candidates
may
replicated
continue
occur
additional
trials
may
otherwise
support
development
specified
indication
actions
advice
food
drug
administration
foreign
regulatory
agencies
may
affect
design
initiation
timing
continuation
progress
clinical
trials
result
need
additional
clinical
trials
company
ability
obtain
maintain
regulatory
approval
product
candidates
labeling
approval
company
reliance
third
parties
assist
conducting
clinical
trials
product
candidates
delays
interruptions
failures
manufacture
supply
company
product
candidates
company
ability
commercialize
product
candidates
size
growth
potential
markets
company
product
candidates
company
ability
service
markets
company
ability
develop
sales
marketing
capabilities
whether
alone
potential
future
collaborators
rate
degree
market
acceptance
company
product
candidates
company
expectations
regarding
ability
obtain
adequately
maintain
sufficient
intellectual
property
protection
product
candidates
timing
outcome
current
future
legal
proceedings
extent
health
epidemics
outbreaks
communicable
diseases
including
could
disrupt
operations
adversely
affect
business
financial
conditions
list
exhaustive
risks
described
company
periodic
reports
including
annual
report
form
quarterly
reports
form
current
reports
form
filed
furnished
securities
exchange
commission
available
statements
company
makes
press
release
speak
date
press
release
company
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
date
press
release
